Moderna shares surge after it says its experimental mRNA cancer treatment passed a key test
Summary
Moderna announced early study results showing that its experimental mRNA cancer vaccine, combined with Merck’s immunotherapy drug Keytruda, helped melanoma patients live longer without cancer coming back compared to Keytruda alone. Following the news, Moderna's stock price more than doubled, and Merck’s shares also increased.Key Facts
- Moderna and Merck are working together on an mRNA cancer vaccine named intismeran.
- Intismeran is designed to be personalized based on the unique mutations in a patient's tumor.
- The study tested intismeran combined with Keytruda against Keytruda alone in melanoma patients.
- Patients receiving the combination treatment had longer periods without cancer returning or spreading.
- The companies did not disclose exact survival times or overall survival benefits yet.
- They plan to share full study results at a future international medical meeting.
- Moderna shares jumped more than 120%, reaching $140.12 per share after the announcement.
- Merck’s shares also rose by about 11% following the news.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
